INNOGEN-B (02591) announced its interim performance, reporting a net loss attributable to shareholders of 115 million yuan, a year-on-year reduction of 5.72%.

18:10 25/08/2026

Yinno Medicine-B (02591) announced its interim results for the six months ended June 30, 2026. The group achieved revenue of 78.218 million yuan (all amounts in yuan), representing a year-on-year increase of 38.57%. The loss attributable to the owners of the parent company was 115 million yuan, a reduction of 5.72% year-on-year; the loss per share was 0.25 yuan.

INNOGEN-B (02591) announced its interim results for the six months ending June 30, 2026, reporting revenue of RMB 78.218 million, an increase of 38.57% year-on-year; the loss attributable to shareholders of the parent company was RMB 115 million, narrowing by 5.72% year-on-year; and the loss per share was RMB 0.25. The announcement stated that the group will commercially launch Ipegufostat for the treatment of T2D in mainland China in February 2025 and in Macao in September 2025. After being included in the national medical insurance drug list for the treatment of adult T2D in December 2025 (effective from January 1, 2026), Ipegufostat continues to gain market coverage and commercial momentum.

DMALL (02586) spent HKD 116,900 to repurchase 25,900 shares on August 25.

ROBOTPHOENIX (06871) released its interim results, with revenue of 186 million yuan, a year-on-year increase of 58.0%.

ZIBUYU (02420) achieved a leap-forward breakthrough in its omni-channel strategy in the first half of the year, realizing a net profit of approximately 138 million yuan, a year-on-year increase of 30.0%.

DMALL (02586) spent HKD 116,900 to repurchase 25,900 shares on August 25.

ROBOTPHOENIX (06871) released its interim results, with revenue of 186 million yuan, a year-on-year increase of 58.0%.